Daily Cosmetic Research Analysis
Three studies advance cosmetic science and safety: a machine learning plus experimental screen flags the cosmetic dye Vat Blue 6 as a thyroid hormone receptor β disruptor; an ultrafast chemiluminescence-based assay enables high-throughput, interference-resistant screening of tyrosinase inhibitors; and a retrospective clinical series with animal histology supports efficacy of an updated 755-nm picosecond laser for photo-aged skin, including in darker skin types.
Summary
Three studies advance cosmetic science and safety: a machine learning plus experimental screen flags the cosmetic dye Vat Blue 6 as a thyroid hormone receptor β disruptor; an ultrafast chemiluminescence-based assay enables high-throughput, interference-resistant screening of tyrosinase inhibitors; and a retrospective clinical series with animal histology supports efficacy of an updated 755-nm picosecond laser for photo-aged skin, including in darker skin types.
Research Themes
- Endocrine disruption risk from cosmetic ingredients
- Assay innovation for screening skin depigmenting agents
- Energy-based device advances for photoaging treatment
Selected Articles
1. Machine Learning-Based Screening of Cosmetic Ingredients Identifies Vat Blue 6 as a Thyroid Hormone Receptor β Disruptor.
Using a curated cosmetic ingredient dataset and a random forest model, the authors prioritized candidates for thyroid hormone receptor β disruption and validated 12 common ingredients in vitro, with six showing measurable TRβ binding. Vat Blue 6, a cosmetic colorant, displayed particularly potent binding consistent with structural mimicry of thyroid hormones, highlighting a potential endocrine risk.
Impact: This integrative computational-experimental workflow identifies a widely used cosmetic dye as a potential TRβ disruptor, informing toxicology, regulation, and consumer safety. It demonstrates a scalable path to proactively screen cosmetic ingredients for endocrine activity.
Clinical Implications: While not immediately practice-changing, the findings support more rigorous safety assessment of cosmetic dyes and may prompt surveillance for thyroid symptoms in susceptible populations. They also guide formulation scientists to consider alternatives to VB6.
Key Findings
- A random forest regression model prioritized cosmetic ingredients for TRβ disruption using a comprehensive ingredient dataset.
- Experimental validation of 12 frequently used cosmetic ingredients found 6 with measurable TRβ binding.
- Vat Blue 6 (VB6) showed potent TRβ binding consistent with thyroid hormone mimicry.
- Results underscore previously unrecognized endocrine disruption potential within cosmetic colorants.
Methodological Strengths
- Integration of machine learning prioritization with in vitro binding assays for experimental confirmation
- Focus on frequently used cosmetic ingredients enhances real-world relevance
Limitations
- In vitro binding does not establish in vivo endocrine effects or dose-response at human exposure levels
- Limited number of compounds validated and focus on TRβ only; other endocrine pathways were not assessed
Future Directions: Conduct receptor transactivation and in vivo endocrine assays, expand validation across chemical classes, quantify consumer exposure and biomonitoring, and evaluate safer colorant alternatives.
Thyroid disorders are among the most prevalent endocrine conditions worldwide, exhibiting a rising incidence and disproportionately affecting women. In this study, we hypothesized that cosmetics may contain previously unidentified thyroid-disrupting chemicals. To evaluate this possibility, we compiled a comprehensive data set of cosmetic ingredients and developed a random forest regression-based machine learning model to predict their potential to disrupt thyroid hormone receptor β (TRβ), a critical regulator of thyroid function. From the top 40 compounds ranked by the model, 12 frequently used cosmetic ingredients were selected for experimental validation. Of these, six demonstrated measurable binding affinity toward TRβ. Notably, Vat Blue 6 (VB6), a colorant utilized in cosmetic formulations, exhibited structural characteristics potentially mimicking thyroid hormones and displayed potent TRβ binding with an affinity (
2. Applying pulse UV irradiation-induced chemiluminescence approach for high-throughput screening assay of tyrosinase inhibitors.
The authors introduce a rapid tyrosinase inhibitor screening assay based on pulse UV-induced chemiluminescence of L-tyrosine with L-012. By immobilizing tyrosinase and washing away inhibitors before activity readout, the method mitigates ROS-scavenging and phenolic interference, delivering sub-minute throughput per sample and results comparable to established assays.
Impact: This method addresses a key source of false results in tyrosinase assays and dramatically increases throughput, accelerating discovery of safer, effective depigmenting agents for cosmetic and medical use.
Clinical Implications: Indirect clinical impact: by enabling better preclinical selection, the assay can reduce downstream failures and safety issues (e.g., ochronosis, cytotoxicity) associated with depigmenting agents.
Key Findings
- Developed a pulse UV-induced chemiluminescence assay for high-throughput tyrosinase inhibitor screening.
- Immobilization and wash steps mitigated ROS-scavenging and phenolic interference artifacts.
- Throughput achieved was less than 1 minute per sample with results comparable to a prior standard assay.
- Environmental and applicability metrics indicated favorable performance.
Methodological Strengths
- Innovative interference-mitigation via enzyme immobilization and washout before activity readout
- Head-to-head statistical comparison with an established assay and reporting of environmental metrics
Limitations
- Purely in vitro; lacks validation in melanocyte/skin models and safety profiling
- Potential residual bias for compounds with complex redox behavior; breadth of chemical classes tested not fully detailed
Future Directions: Validate hits in cellular melanogenesis models, integrate cytotoxicity profiling, and adapt the platform for multiplexed screening and kinetic analyses.
Tyrosinase is an enzyme that metabolizes L-tyrosine and is found in various organisms. Its overactivity can lead to health issues in humans, such as hyperpigmentation, and can adversely affect human skin, leading to skin cancers. This has heightened the significance of tyrosinase inhibitors in pharmaceuticals and cosmetics, particularly skin-whitening formulations. In this study, we developed a high-throughput screening assay for identifying tyrosinase inhibitors. This assay leverages the strong chemiluminescence signal emitted by L-tyrosine upon nanosecond UV irradiation in the presence of L-012 chemiluminescence dye, which is based on the formation of reactive oxygen species (ROS). We measured the decrease in chemiluminescence signal induced by tyrosinase enzyme, which converts chemiluminescent L-tyrosine into non-chemiluminescent L-DOPA. The addition of tyrosinase inhibitors prevents this conversion, leading to recovery in chemiluminescence of L-tyrosine. However, the reliability of the assay can be compromised by the ROS-scavenging activity and phenolic nature of certain enzyme inhibitors. To mitigate potential false results caused by some inhibitors, tyrosinase was immobilized on the microplate surface, and the inhibitors were incubated with the fixed enzyme, then, the enzyme activity was assessed after washing away the inhibitors. The proposed assay successfully facilitated high-throughput screening (less than 1 min per sample) of numerous tyrosinase inhibitor candidates from various pharmacological classes. The percentage inhibition of tyrosinase activity determined by our assay was statistically compared with results from a previously reported assay, revealing comparable outcomes and confirming the reliability of our approach. In addition, we evaluated the environmental impact and applicability of the assay using two recent metrics, yielding promising results.
3. Clinical and histologic changes after 755-nm picosecond laser with a novel platinum focus lens array in the treatment of photo-aged skin.
In a 10-patient retrospective series (Fitzpatrick IV–V) and a complementary porcine model, an updated 755-nm picosecond laser with a novel focus lens array improved wrinkles, pores, and pigmentation with minimal downtime. Histology demonstrated epidermal vacuoles, superficial dermal RBC extravasation, increased dermal thickness, and elevated collagen I expression, consistent with laser-induced optical breakdown and dermal remodeling.
Impact: Provides early clinical outcomes in darker skin types with mechanistic histology, supporting safe adoption of an updated picosecond platform for photoaging.
Clinical Implications: Supports use of 755-nm picosecond laser with a novel lens array for photo-aged skin and pigmentary concerns with minimal downtime; encourages parameter optimization and prospective controlled trials for long-term outcomes.
Key Findings
- Retrospective 10-patient series (Fitzpatrick IV–V) showed notable aesthetic improvements with minimal complications.
- Porcine histology revealed epidermal vacuoles and superficial dermal RBC extravasation immediately post-treatment.
- Dermal thickness and collagen type I expression increased across energy settings, indicating dermal remodeling.
- Findings support laser-induced optical breakdown as a mechanism for rejuvenation.
Methodological Strengths
- Combined clinical assessment with standardized photography and animal histology
- Evaluation across multiple energy settings with immunohistochemical analyses
Limitations
- Small, retrospective, uncontrolled human sample with subjective outcome measures
- Follow-up duration and durability of effects not clearly reported
Future Directions: Prospective randomized comparisons versus other rejuvenation modalities, objective biomechanical and pigment quantification, and safety profiling in diverse skin types.
The 755-nm picosecond laser device has undergone recent updates. A comprehensive evaluation is warranted to summarize and recognize efficacy and safety profiles of the 755-nm picosecond laser with a novel platinum focus lens array for skin lightening and rejuvenation. A retrospective analysis was conducted on patients who received treatment with the updated 755-nm picosecond laser device. Standardized clinical photographs were taken prior to treatment and during follow-up assessments. A modified global aesthetic improvement scale was employed as the main evaluation indicator. Additionally, the abdomens of 4-week-old Bama miniature pigs were treated with the new laser device. Histological changes were examined using hematoxylin and eosin staining, Masson's Trichrome staining, and immunohistochemical techniques. The study involved 10 patients with Fitzpatrick skin types IV to V, presenting with wrinkles, enlarged pores, and pigmented lesions. Notable improvements were observed, accompanied by minimal downtime and complications. Histological analysis conducted immediately after treatment revealed the presence of vacuoles within the epidermis and extravasation of red blood cells in the superficial dermis. Furthermore, dermal thickness exhibited a significant increase following treatment across all energy settings. The expression of collagen type I proteins also showed an increase post-treatment with the new device. The newly developed 755-nm picosecond laser device effectively induces laser-induced optical breakdown and initiates dermal remodeling. It represents a safe and effective therapeutic option for facial rejuvenation.